We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Invitrogen Enters into Agreement with genOway in RNAi Field

Invitrogen Enters into Agreement with genOway in RNAi Field

Invitrogen Enters into Agreement with genOway in RNAi Field

Invitrogen Enters into Agreement with genOway in RNAi Field

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Invitrogen Enters into Agreement with genOway in RNAi Field"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation and genOway have announced the signing of a co-marketing agreement around RNAi related services.

Under the terms of the agreement, Invitrogen and genOway will combine Invitrogen's expertise in RNAi research technologies with genOway's portfolio of transgenesis technologies and RNAi in vivo experience to create a services platform offering RNAi vector design through the creation of RNAi transgenic rodent models.

"Combining the services of these two leading RNAi companies will provide researchers with a complete solution to ensure successful RNAi research for drug discovery and therapeutic applications," said Jon Hindar, Senior Vice President of Life Sciences at Invitrogen.

"This broad service offering has the potential to significantly accelerate target validation studies in disease research."

"RNAi continues to gain acceptance in drug discovery and development applications," explained Kader Thiam, Head of Transgenic technologies of genOway.

"Our leading in vivo RNAi technologies are strengthened by the solid in vitro applications Invitrogen has developed."

Invitrogen has built an RNAi technology portfolio in recent years, first offering a family of products under the BLOCK-iT™ name in September 2003, including short interfering RNA, kits for creating short hairpin RNA, and technologies to deliver RNAi reagents to cells and tissues.

In November 2003, Invitrogen announced that it had acquired privately-held Sequitur, Inc. of Natick, Mass. Sequitur brought to Invitrogen Stealth™ technology, a proprietary synthetic RNA molecule that holds advantages over traditional siRNA in specificity, efficacy, stability and reducing "off target" effects of silencing.

This year Invitrogen launched the BLOCK-iT™ pol II miR RNAi expression vector kits and services which combine the advantages of traditional RNAi vectors with capabilities for tissue specific expression and multiple target knockdown from the same transcript.